Results and Takeaways From a 12-month Claims Analysis of Ruxolitinib

Opinion
Video

Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, reduced rescue medication use, fewer dermatology visits, and a favorable safety profile compared to standard treatments, supporting its role as a valuable non-steroidal topical option for long-term management.

Recent Videos
2 experts in this video
2 experts in this video
1 expert in this video
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.